Article

An American Journal of Managed Care® Symposium: Examining Treatment Advancements in Psoriasis and Psoriatic Arthritis

Related Videos
April Armstrong, MD, MPH, chief of dermatology, UCLA
April Armstrong, MD, MPH, chief of dermatology, UCLA
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Cente
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Joseph Zabinksi, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology
Related Content
Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis

Pearl Steinzor
Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021

Psoriasis as an Inflammatory Disease, and What’s Changed Over Time

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Medicines on shelf - Prasanth - stock.adobe.com.jpg
April 24th 2025

Rising Costs of Biologics for Plaque Psoriasis Highlight Savings Potential

Pearl Steinzor
Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.
Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
April 10th 2025

Icotrokinra Shows Clear Skin in 75% of Adolescents With Plaque Psoriasis in Phase 3 Trial

Pearl Steinzor
New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.
Psoriasis oral treatment | Image credit: Pawel - stock.adobe.com
April 7th 2025

Women Have Lower Drug Survival With Biologics for Psoriasis, Including IL-17 and IL-23 Inhibitors

Pearl Steinzor
Biologics for psoriasis had lower drug survival in women compared with men, according to one study.
Psoriasis treatment concept | Sviatlana - stock.adobe.com
April 1st 2025

Tildrakizumab Effective Up to Nearly 3 Years Regardless of BSA Affected, Obesity

Pearl Steinzor
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo